A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment

Yasuo Hamamoto, Tomomi Komaki, Junko Miyamoto, Noriyuki Akutsu, Etsuko Warita, Yasuhiro Yamanaka, Yoshinori Kuroki, Hirofumi Shirakawa, Heita Ozawa, Morihiro Tomikawa, Shoichi Hishinuma, Sayuri Hoshi, Seiji Igarashi, Tomoe Ozasa, Yasuyoshi Sugano, Kenjiro Kotake

Research output: Contribution to journalArticle

Abstract

The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer (mCRC) has significantly improved outcomes. There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy. For patients with isolated liver metastases, surgical resection is recommended when feasible. We experienced a case in which an initially unresectable mCRC liver metastases converted into a resectable one after cetuximab monotherapy as third-line treatment. The sample from hepatectomy was a pathologically complete response; no remnants were detected. The management of liver metastases contributes to improvements in the clinical setting. For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepatic surgeons and diagnostic/therapeutic radiologists is indispensable. Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable CRC liver metastases in each hospital.

Original languageEnglish
Pages (from-to)1017-1019
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number6
Publication statusPublished - 2011 Jan 1
Externally publishedYes

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Liver
Combined Modality Therapy
Hepatectomy
Therapeutics
Clinical Protocols
Monoclonal Antibodies
Drug Therapy
Cetuximab

Keywords

  • Cetuximab
  • Colorectal cancer
  • Conversion therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment. / Hamamoto, Yasuo; Komaki, Tomomi; Miyamoto, Junko; Akutsu, Noriyuki; Warita, Etsuko; Yamanaka, Yasuhiro; Kuroki, Yoshinori; Shirakawa, Hirofumi; Ozawa, Heita; Tomikawa, Morihiro; Hishinuma, Shoichi; Hoshi, Sayuri; Igarashi, Seiji; Ozasa, Tomoe; Sugano, Yasuyoshi; Kotake, Kenjiro.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 6, 01.01.2011, p. 1017-1019.

Research output: Contribution to journalArticle

Hamamoto, Y, Komaki, T, Miyamoto, J, Akutsu, N, Warita, E, Yamanaka, Y, Kuroki, Y, Shirakawa, H, Ozawa, H, Tomikawa, M, Hishinuma, S, Hoshi, S, Igarashi, S, Ozasa, T, Sugano, Y & Kotake, K 2011, 'A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment', Japanese Journal of Cancer and Chemotherapy, vol. 38, no. 6, pp. 1017-1019.
Hamamoto, Yasuo ; Komaki, Tomomi ; Miyamoto, Junko ; Akutsu, Noriyuki ; Warita, Etsuko ; Yamanaka, Yasuhiro ; Kuroki, Yoshinori ; Shirakawa, Hirofumi ; Ozawa, Heita ; Tomikawa, Morihiro ; Hishinuma, Shoichi ; Hoshi, Sayuri ; Igarashi, Seiji ; Ozasa, Tomoe ; Sugano, Yasuyoshi ; Kotake, Kenjiro. / A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment. In: Japanese Journal of Cancer and Chemotherapy. 2011 ; Vol. 38, No. 6. pp. 1017-1019.
@article{6f333c2d51f940af99caec77cc0bf19a,
title = "A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment",
abstract = "The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer (mCRC) has significantly improved outcomes. There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy. For patients with isolated liver metastases, surgical resection is recommended when feasible. We experienced a case in which an initially unresectable mCRC liver metastases converted into a resectable one after cetuximab monotherapy as third-line treatment. The sample from hepatectomy was a pathologically complete response; no remnants were detected. The management of liver metastases contributes to improvements in the clinical setting. For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepatic surgeons and diagnostic/therapeutic radiologists is indispensable. Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable CRC liver metastases in each hospital.",
keywords = "Cetuximab, Colorectal cancer, Conversion therapy",
author = "Yasuo Hamamoto and Tomomi Komaki and Junko Miyamoto and Noriyuki Akutsu and Etsuko Warita and Yasuhiro Yamanaka and Yoshinori Kuroki and Hirofumi Shirakawa and Heita Ozawa and Morihiro Tomikawa and Shoichi Hishinuma and Sayuri Hoshi and Seiji Igarashi and Tomoe Ozasa and Yasuyoshi Sugano and Kenjiro Kotake",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "38",
pages = "1017--1019",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment

AU - Hamamoto, Yasuo

AU - Komaki, Tomomi

AU - Miyamoto, Junko

AU - Akutsu, Noriyuki

AU - Warita, Etsuko

AU - Yamanaka, Yasuhiro

AU - Kuroki, Yoshinori

AU - Shirakawa, Hirofumi

AU - Ozawa, Heita

AU - Tomikawa, Morihiro

AU - Hishinuma, Shoichi

AU - Hoshi, Sayuri

AU - Igarashi, Seiji

AU - Ozasa, Tomoe

AU - Sugano, Yasuyoshi

AU - Kotake, Kenjiro

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer (mCRC) has significantly improved outcomes. There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy. For patients with isolated liver metastases, surgical resection is recommended when feasible. We experienced a case in which an initially unresectable mCRC liver metastases converted into a resectable one after cetuximab monotherapy as third-line treatment. The sample from hepatectomy was a pathologically complete response; no remnants were detected. The management of liver metastases contributes to improvements in the clinical setting. For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepatic surgeons and diagnostic/therapeutic radiologists is indispensable. Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable CRC liver metastases in each hospital.

AB - The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer (mCRC) has significantly improved outcomes. There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy. For patients with isolated liver metastases, surgical resection is recommended when feasible. We experienced a case in which an initially unresectable mCRC liver metastases converted into a resectable one after cetuximab monotherapy as third-line treatment. The sample from hepatectomy was a pathologically complete response; no remnants were detected. The management of liver metastases contributes to improvements in the clinical setting. For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepatic surgeons and diagnostic/therapeutic radiologists is indispensable. Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable CRC liver metastases in each hospital.

KW - Cetuximab

KW - Colorectal cancer

KW - Conversion therapy

UR - http://www.scopus.com/inward/record.url?scp=84866989938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866989938&partnerID=8YFLogxK

M3 - Article

C2 - 21677499

AN - SCOPUS:84866989938

VL - 38

SP - 1017

EP - 1019

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -